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Abstract
For genetic research to contribute more fully to furthering our knowledge of neuropathic pain, we require an agreed, valid, and feasible
approach to phenotyping, to allow collaboration and replication in samples of sufficient size. Results from genetic studies on
neuropathic pain have been inconsistent and havemetwith replication difficulties, in part becauseof differences in phenotypes used for
case ascertainment. Because there is no consensus on the nature of these phenotypes, nor on the methods of collecting them, this
study aimed to provide guidelines on collecting and reporting phenotypes in cases and controls for genetic studies. Consensus was
achieved through a staged approach: (1) systematic literature review to identify all neuropathic pain phenotypes used in previous
genetic studies; (2) Delphi survey to identify the most useful neuropathic pain phenotypes and their validity and feasibility; and (3)
meeting of experts to reach consensus on the optimal phenotype(s) to be collected from patients with neuropathic pain for genetic
studies. A basic “entry level” set of phenotypes was identified for any genetic study of neuropathic pain. This set identifies cases of
“possible” neuropathic pain, and controls, and includes: (1) a validated symptom-basedquestionnaire to determinewhether any pain is
likely to be neuropathic; (2) body chart or checklist to identify whether the area of pain distribution is neuroanatomically logical; and (3)
details of pain history (intensity, duration, any formal diagnosis). This NeuroPPIC “entry level” set of phenotypes can be expanded by
more extensive and specific measures, as determined by scientific requirements and resource availability.
Keywords: Neuropathic pain, Genetics, Phenotype, Systematic review, Delphi survey
1. Introduction
Genetic analysis of neuropathic pain will illuminate the biological
processes underlying the condition and facilitate identification of
novel therapeutic and prevention targets. However, the clinical utility
of findings from current research is questionable, with limited
success in identifying the genes contributing to the heritable risk,
and difficulties in replicating the documented genes.28,32 Future
genome-wide association and candidate gene studies will likely
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identify the genetic contribution to neuropathic pain heritability, as
has happened with various complex central nervous system
disorders, if sufficiently powered sample sizes are used.17,41
Although measures to ensure the quality and validity of genetic
analysis arewell established,1,10,38 there is little agreement onwhich
neuropathic pain traits should be studied and which phenotyping
tools to use. The quality and validity of the phenotype are as
important as thoseof the geneticmethodology,50 andperhapseven
more important than sample size.30 A poorly defined or quantified
phenotypewill produce errors in effect size estimation, loss of power
to identify risk genes, or identification of significant associationswith
phenotypes with limited clinical relevance.24,33
An optimally collected phenotype should fully describe the
neuropathic pain entity under study every time and capture the
samegenetic variants in replicated studies. It shouldbecollectedwith
validated instruments (ie, accurate, precise, reproducible,with known
positive and negative predictive values) that are practical (ie, simple to
implement, efficient, cost-effective) and ethical. No single phenotyp-
ing instrument will encompass all these requirements. Rather,
a number of instruments are required, ranging from “highly specific”
tools to “very general.” These instruments should be mutually
consistent and able to diagnose participants by classifying them as
“possibly,” “probably”, or “definitely” having neuropathic pain.47
Classificationof controls is as important asclassificationof cases, and
both require stringencyandclarity.30 Tailoring the right combinationof
instruments for any particular study depends on a balance between
validity and feasibility.
There is currently no “gold standard” for assessing neuropathic
pain, for clinical or research purposes. There is, however, growing
consensus, with generally minor variations between
approaches.19,44 Consensus on neuropathic pain phenotyping in
genetic research will facilitate: (1) scientific collaboration, increasing
the potential to combine cohorts to achieve larger sample sizes; (2)
replication of gene discoveries; (3) meta-analyses; and (4) trans-
lation from laboratory to general population, and vice versa.43
Furthermore, until very large samples are created purely for
researching neuropathic pain, population-based research will rely
on data from multipurpose clinical samples. Although the lack of
a “gold standard” currently precludes calculation of precise positive
and negative predictive values, the existence of an agreed standard
for neuropathic pain will facilitate a valid approach to this research.
Led and funded by the International Association for the Study
of Pain (IASP) Special Interest Group (SIG) on Neuropathic Pain
(NeuPSIG), and in collaboration with the IASP SIG on Genetics
and Pain, we staged an approach towards achieving consensus
on neuropathic pain phenotyping for human genetic studies. This
is intended to inform future genetic research, rather than
phenotyping for clinical research or clinical diagnosis.
2. Methods
Our step-wise approach towards this goal had 3 stages:
(1) A systematic literature review to identify all neuropathic pain
phenotypes used in previous genetic studies;
(2) A Delphi survey to determine and rank neuropathic pain
phenotypes assessing their validity and feasibility; and
(3) Ameeting of experts to reach consensus on “ideal” phenotype
(s) to be collected from patients with neuropathic pain for
genetic studies.
2.1. Systematic review
2.1.1. Aim
To conduct a systematic literature review to identify and compare
phenotypes used in genetic studies of noncancer neuropathic
pain in adults for the purposes of informing the phenotypes that
may best capture the genetic architecture of neuropathic pain for
human genetic studies.
2.1.2. Study selection and data extraction
Electronic databases MEDLINE, EMBASE, SCOPUS, Science
Direct, ISI Web of Science, and CINAHL were searched from
January 1966 to April 2014 for English language papers.We used
the same search strategy as a recent systematic review to identify
neuropathic pain48 and combined this with broad search terms
for “genetic studies.” These search terms are listed in Supple-
mentary Digital Content 1 (available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A147).
We excluded studies in which: (1) it was not possible to
distinguish between participants with neuropathic pain and those
with nonneuropathic pain (including mixed pain conditions); (2) the
pain was cancer related; (3) the condition was not currently defined
by the IASP as neuropathic pain (complex regional pain syndrome,
temporomandibular disorders, migraine, chronic widespread pain
[CWP], and fibromyalgia)26; or (4) the study was in children.
Database searches were conducted by one author (O.v.H.).
Article titles and then abstracts were reviewed for possible
inclusion by 2 authors (O.v.H. and B.H.S.), before full-text
versions of the remaining articles were reviewed and the final
selection was confirmed. We extracted data on: (1) study
characteristics (country, sample population, study design); (2)
phenotyping methods described; (3) sample size (cases and
controls); (4) the specific neuropathic pain condition(s) under
study; and (5) genetic factors investigated.
We differentiated between “brief” and “detailed” phenotype
descriptions to give an indication of the level of detail provided by
the authors and whether or not it allowed replication by other
researchers. For example, “Clinical examination by pain specialist”15
was regarded as “brief,” whereas “Clinical examination: straight leg
raising test, manual testing ofmotor and sensory defects of the lower
extremitiesconcordantwithmagnetic resonance imaging findings,”35
was regarded as “detailed.” This does not necessarily indicate that
only a brief examination was conducted in the former case, but
indicates the extent to which the phenotyping was described.
In addition to extracting descriptive information, the phenotype
information was assessed against the neuropathic pain grading
guidelines published by NeuPSIG47 and approved by the IASP.26
This ranks the diagnostic certainty with which the presence or
absence of neuropathic pain can be based on the neuroana-
tomical distribution of symptoms, patient history, and tests
confirming the underlying nervous system lesion or disease. The
grading system has the following criteria: (1) pain with a neuro-
anatomically plausible distribution; (2) a history of a relevant lesion
or disease affecting the somatosensory system; (3) confirmatory
tests demonstrating the presence of negative and positive
sensory signs confined to innervation territory of the lesioned
nervous structure; and (4) further diagnostic tests confirming
a causative lesion or disease entity. Criteria 1 and 2 must be met
to allow a working hypothesis of “possible” neuropathic pain.
Additionally, criterion 3 or criterion 4must also bemet to reach the
grade of “probable” neuropathic pain. If all 4 criteria are satisfied,
the grade of “definite” neuropathic pain is achieved.
2.2. Delphi survey
2.2.1. Aim
The aim was to obtain expert consensus on phenotype compo-
nents that should be used to determine “caseness” in genetic
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studies of neuropathic pain and to grade the validity and feasibility of
applying these phenotype components in research setting.
2.2.2. Ethics approval
The study had ethics approval from the University of Dundee
Research Ethics Committee (UREC 14032).
2.2.3. Participants
E-mail invitations to take part in a 3-roundDelphi surveywere sent
to 28 experts in the field of neuropathic pain phenotyping and/or
conducting genetic studies on neuropathic pain. All experts were
identified by their publication track record in at least one of the
fields. The invitation provided information on the context and
objectives of the Web-based survey (composed using the
SurveyMonkey software application at https://www.surveymon-
key.com) and a hyperlink for interested individuals to access the
survey. Participation was voluntary, and anonymity was assured.
At the end of the first round of the survey, respondents
indicated whether they wanted to take part in subsequent
rounds. Respondents who elected to continue participating were
sent e-mail invitations that included a summary of the results from
the previous round, and a hyperlink to a new Web-based
questionnaire. Round 3 was only completed after the face-to-
face consensus meeting (see 2.3. Consensus meeting).
2.2.4. Questionnaires
In round 1, expert panelists used a 5-point Likert scale (15 strong
disagreement, 3 5 no agreement or disagreement, 5 5 strong
agreement) to rate the level of their agreement with statements
regarding: (1) the sensitivity and specificity of symptoms, clinical
signs, and additional investigations (eg, quantitative sensory
testing [QST], nerve conduction studies) when diagnosing
neuropathic pain; (2) the feasibility of nonexpert clinicians and
researchers to accurately assess items in the 3 measurement
domains (symptoms, clinical signs, and additional investigations);
(3) whether symptoms and clinical signs could be self-assessed
by study participants; and (4) whether the assessment of medical
history, body charts of perceived pain, quality of life, and
psychological factors should also be phenotyped in population-
based genetic studies. The expert panelists were also asked to
list up to 4 symptoms, signs, and additional investigations that
they thought provided the best balance between feasibility and
validity when assessing whether a pain was predominantly
neuropathic in nature. Finally, respondents rated the level of
diagnostic certainty (none, possible, probable, or definite) they
thought was achieved by 9 different assessment combinations.
The 9 assessment combinations were: symptoms only; symp-
toms, body chart of perceived pain and pain history; clinical signs
only; clinical signs and symptoms; clinical signs, symptoms, body
chart of perceived pain and pain history; additional investigations
only; additional investigations and clinical signs; additional
investigations, clinical signs, and symptoms; and additional
investigations, clinical signs, symptoms, and body chart of
perceived pain and pain history. These assessments were
derived from the neuropathic pain grading system developed
by Treede and et al.47 The order of the 9 combinations was
randomized for each panelist.
In round 2, following the standard Delphi methodology, to allow
re-evaluation of responses in light of those of their peers,13,39
panelists were shown summary results from round 1. They were
asked again for their responses to questions on measurement
sensitivity, specificity, feasibility, whether participants could self-
complete a diagnostic questionnaire, and on the resultant
diagnostic certainty. Based on responses to round 1, panelists
were also provided with a list of 14 verbal descriptors of their pain
symptoms (hot/burning, stabbing, itching, numbness, electric
shocks/shooting, pricking/tingling/pins and needles, pain in an
area of numbness, pain in a plausible anatomical distribution,
pain evoked by light touch, pain in an area of altered sensation,
spontaneous pain, evoked pain, painful cold, and paroxysmal
pain), 12 clinical signs (dynamic mechanical allodynia, deep
mechanical allodynia, altered sensation to punctate mechanical
stimuli, static mechanical hyperalgesia, hypoesthesia to punctate
mechanical stimuli, altered reflexes, punctate mechanical hyper-
algesia, thermal hyperalgesia, cold allodynia, altered vibration
sense, thermal hypoesthesia, and temporal summation), and 5
additional investigations (QST, cerebral evoked potentials, intra-
epidermal nerve fiber density, magnetic resonance imaging, and
nerve conduction studies). From each of these lists, panelists
were asked to rank in descending order of importance the 5 items
they thought provided the best balance between validity and
feasibility when making a diagnosis of neuropathic pain. The
order of items in each list was randomized for each panelist.
Finally, based on feedback from the first round, panelists were
asked to identify up to 4 additional phenotype components that
could be added to the assessment of study participants once
“caseness” had been established, which would allow more
complex phenotypes to be collected.
In round 3, respondents were shown summary results from
round 2, and asked to rerate their ranking of the 5 most valid and
feasible symptoms, clinical signs, and additional investigations to
use when making a diagnosis of neuropathic pain. In addition,
based on discussions at the face-to-face consensus meeting
(see 2.3. Consensusmeeting), which took place between round 2
and 3 of the Delphi survey, respondents were asked to rate their
agreement on a 5-point Likert scale (1 5 strong disagreement
and 55 strong agreement) with statements regarding the patient
history and using a pain body chart. Because these additional
questions were only asked once, responses were analyzed
separately from the rest of the Delphi survey.
2.2.5. Data analysis
Consensus in Delphi surveys is said to have been achieved when
a given proportion of participants agree on an item under debate;
this proportion varies between studies. For this study, achieve-
ment of “good” consensus was assumed when $70% of
respondents agreed, and “strong” consensus was assumed
when there was $90% agreement.44
2.3. Consensus meeting
2.3.1. Aim
The aim was to develop a consensus statement on an approach to
phenotyping in genetic studies of neuropathic pain in adults and to
identify a basic or “entry level” phenotype for any such study.
2.3.2. Procedure
The meeting was held in Versailles, France, from June 12 to 13,
2014, and consisted of 18 experts, identified by NeuPSIG based
on their experience in the fields of pain phenotyping, epidemiol-
ogy, and/or pain genetics. Represented disciplines included
neurology, anaesthesiology, pain medicine, palliative care,
primary care, basic neuroscience, and genetics. Activities on
the first day included: (1) describing the aims of the meeting and
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defining the questions that were to be addressed; (2) presentation
of data from the systematic literature review and the results of the
first 2 rounds of the Delphi survey; and (3) short presentations by
panelists on the differences and commonalities between
“phenotyping” (what information to collect and how to collect it)
to collect vs “phenomics” (which pain phenotypes should be used
in genetic association analysis), phenotyping of complex dis-
eases, phenotyping by questionnaires, phenotyping by clinical
examination, phenotyping using standard and dynamic QST, and
phenotyping for clinical trials. Each presentation by a panelist was
followed by discussion. Activities on the second day included
parallel breakaway discussions followed by plenary-based
consensus. These focused on (1) the availability and use of
validated diagnostic neuropathic pain screening tools, (2) the level
of diagnostic certainty achieved when defining cases and
controls, and (3) generating a consensus definition and the
requirements of what should be “entry level” phenotyping
requirements for genetic studies on neuropathic pain. All
participants in the consensus meeting contributed as authors of
this article.
3. Results
3.1. Systematic literature review
From an initial 4827 article titles identified through searching
electronic databases and handsearching, 3372were identified as
unique records. Of these, 21 articles fulfilled the inclusion criteria
and underwent data extraction (Fig. 1).
3.1.2. Characteristics of included studies
Six studies analysed Nordic populations,6,15,22,23,27,35 5 analysed
other European populations,2,4,16,20,40 3 analysed Japa-
nese,36,42,45 2 analysed Israeli-Jewish12,34 and South African
Figure 1. Systematic review: PRISMA flow diagram of article identification, assessment, and inclusion.
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black, Caucasian, and Indian,21,49 1 analysed Chinese (Taiwan),8
and 1 analysed Caucasian-, African-, and Hispanic-American
populations.46 One study included 5 cohorts with various
neuropathic pain conditions from 4 populations (Danish, Finnish,
Israeli-Jewish, and Caucasian-, African-, and Hispanic-Ameri-
can).11 Two studies on postherpetic neuralgia (PHN) recruited
participants from the same Japanese population.36,45 Several
studies reused the same cohorts to investigate different poly-
morphisms, namely 2 studies on a South African HIV-positive
cohort comprising African black, Caucasian, and Indian,21,49 2
studies on aNorwegian cohort with discogenic sciatic pain,22,23 2
studies on Caucasian-, African-, and Hispanic-American patients
with persistent pain after surgery for discogenic sciatic pain,11,46
and 3 studies on a Finnish cohort with discogenic pain.11,27,35
A variety of causes of neuropathic pain were studied (Table 1).
Four study cohorts grouped together a number of causes of
neuropathic pain,2,4,11,15 whereas others focused on a solitary
cause of neuropathic pain.6,8,12,16,20–23,27,34–36,40,42,45,46,49
Overall, most associations reported between genotype and risk
of neuropathic pain/intensity of neuropathic pain have been
isolated findings that have not yet been replicated, or failed to
replicate as conflicting findings have been reported. Although
there have been consistent reports of genetic associations at
specific loci, some of the replication studies included patients
with postherpetic neuralgia recruited from the same study
site36,45 or from the same study cohort27,35 (ie, patients having
discogenic sciatic pain) (Table 2). Only 3 studies included a priori
replication cohorts into their study designs.11,15,46
3.1.3. Phenotyping methods
The identified studies could be classified into 3 broad categories,
according to their reason for phenotyping neuropathic pain: (1) to
determine whether any pain was neuropathic (identification of cases
and controls)2,4,8,12,15,16,20,22,23,34–36,42,45,49; (2) to identify endo-
phenotypes within cohorts with neuropathic pain (ie, phenomics)
6,11,21,27,40,46,49; and (3) to identify pain (not specifically neuropathic)
in a neurological condition, eg, multiple sclerosis.16
Table 3 and Supplementary Digital Content 2 (available
online as Supplemental Digital Content at http://links.lww.com/
PAIN/A148) provide summaries of the phenotyping methods
described in these articles. Overall, “clinical examination” was
the most frequently reported phenotyping method; described
in 15/21 studies, with “brief examination” reported in 6 studies,
including in total 1742 cases, and “detailed examination”
reported in 9 studies (1346 cases). “Pain-rating scales” (either
visual analogue or numerical rating scales, 2786 cases) and
“history” (2552 cases) were the next most common phenotyp-
ing method described, with 13/21 studies each. With “Pain-
rating scales,” only half of these articles described what the
relevance of the pain score was: for example, to be used as
a cutoff for “caseness” to categorize patients as “cases” or
Table 1
Systematic review: description of cases and controls in included studies.
Study Sample size Cases Controls
Cases Controls
Armero et al.2 144 139 Sympathetic reflex dystrophy, complex regional
pain syndrome II, failed low-back surgery
syndrome, phantom limb pain, peripheral nerve
neuralgia, cranial nerve neuralgia, postherpetic
neuralgia
Age-matched healthy subjects without
a history of pain
Binder et al.4 371 252 Complex regional pain syndrome, postherpetic
neuralgia, peripheral nerve injury, trigeminal
neuropathy, polyneuropathy, central pain, other
neuropathies
Healthy German volunteers (all Caucasian)
Brasch-Andersen et al.6 11 23 Polyneuropathy—patients with moderate or
better pain relief during escitalopram treatment
were categorized as “responders” (cases)
Polyneuropathy—patients with less than
moderate pain relief during escitalopram
treatment were categorized as “non-
responders” (controls)
Cheng et al.8 15 50 Painful diabetic peripheral neuropathy (with
foot ulcer)
Painless diabetic peripheral neuropathy
(with foot ulcer)
Costigan et al.11 1174 (total from 5 cohorts)* NA Chronic lumbar root pain after surgical
discectomy (n 5 151), limb amputation (n 5
199), sciatica (n 5 195), phantom limb pain
(n 5 100), postmastectomy pain syndrome
(n 5 529)
No control group was used (authors
modelled the relationship between
genotype and pain intensity within the
cohorts)
Dabby et al.12 9 50 Chronic severe unexplained neuropathic pain Not described
Dominguez et al.15 325 (total from 2 cohorts) 731 (total from 3
cohorts)
Persistent postsurgical pain (PPSP) after
inguinal hernia repair (n 5 94), radicular
neuropathy from lumbar disk herniation
(n 5 231)
No PPSP (n 5 95), Swedish national
population register for a multiple sclerosis
incidence study (n 5 213), and the
Diabetes Incidence Study in Sweden (n5
423; matched to cases by age, sex, and
geographic region)
No control group was used for the
radicular neuropathy group (authors
modelled the relationship between
genotype and pain intensity/functional
recovery within the cohort)
(continued on next page)
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“controls.” Nine of the articles reporting a “history” provided
a “brief history” (2226 cases), and 4 of the articles provided
a “detailed history” (326 cases). All other phenotyping methods
were described in fewer than half of the articles, with the least
frequently reported phenotyping methods being “nerve con-
duction studies” (2/21), “intraepidermal nerve fibre density”
(2/21), “inflammatory markers” (2/21), “body chart of perceived
pain” (1/20), and related “psychiatric measures” (1/21). In 2
studies, there was phenotyping heterogeneity, manifesting in
the use of more than 1 sample population cohort within the
same study.11,15
The only specific neuropathic pain symptom questionnaire
reported was the AIDS Clinical Trials Group Brief Peripheral
Neuropathy Screen.9,21,49 No studies reported the use of
validated case ascertainment tools such as the Douleur Neuro-
pathique en 4 questions (DN4),5 Leeds Assessment of Neuro-
pathic Symptoms and Signs (LANSS),3 or painDETECT.18
The control groups described in the studies could be divided
into 3 broad categories: (1) healthy volunteers,2,4,16,35,36,42,45
(2) population-specific national reference cohorts,15,22,23 and
(3) diseased controls.6,8,15,16,20,27,34,49 Three studies used
more than 1 category of control group.15,16,45 In the first 2
categories (healthy controls and population-specific national
reference cohorts), little or no information was provided on the
phenotyping of controls. Typically, the information provided in
these studies was restricted to whether the controls were
healthy, genetically unrelated, and matched the cases for
various demographic variables. Diseased controls were de-
fined as having the same disease or aetiology as the cases, but
were not considered to have neuropathic pain at the time of the
study.
Four studies modelled genotype against intensity of neuro-
pathic pain and thus did not include control groups.11,21,46,49
Similarly, 2 case reports did not include control groups at all.12,40
Table 1 (continued)
Study Sample size Cases Controls
Cases Controls
Ferna´ndez de-las-Pen˜as
et al.16
58 108 (total from 2
cohorts)
Pain in multiple sclerosis (36 with neurogenic
pain)
Pain-free multiple sclerosis (n5 50), and
age- and sex-matched, pain-free healthy
subjects from the general population with
specific exclusion criteria (n 5 108)
Hegarty and Shorten20 20 33 Persistent postsurgical pain (PPSP) after
lumbar discectomy
No PPSP (n 5 33)
Hendry et al.21 158 NA HIV-associated sensory neuropathy (HIV-SN) No control group was used (authors
modelled the relationship between
genotype and pain intensity within the
cohort)
Jacobsen et al.23 258 249 Lumbar disk herniation and sciatic pain. Pain-free controls collected from the
general health survey Nord-Trøndelag
Health Study (HUNT). Controls had no
history of back disease, and were matched
for age, sex, and smoking status
Jacobsen et al.22 257 253 Lumbar disk herniation and sciatic pain. Pain-free controls collected from the
general health survey Nord-Trøndelag
Health Study (HUNT). Controls had no
history of back disease, and were matched
for age, sex, and smoking status
Karppinen et al.27 14 139 GGGA interleukin (IL)-6 haplotype with
unilateral discogenic sciatic pain
Non-GGGA IL-6 haplotype with unilateral
discogenic sciatic pain
Nissenbaum et al.34 21 334 PPSP after unilateral breast mastectomy or
lumpectomy
No PPSP after unilateral breast
mastectomy or lumpectomy
Noponen-Hietala et al.35 155 179 Unilateral discogenic sciatic pain Unrelated University of Oulu, Finland,
employees and students (aged 20-69 y),
all of whom were Finnish. No data were
collected concerning possible
musculoskeletal disorders
Ozawa et al.36 32 136 Postherpetic neuralgia (PHN) Unrelated healthy Japanese volunteers
Ramirez et al.40 6 0 Charcot-Marie-Tooth disease (hereditary
painful neuropathy)
No controls reported
Sato et al.42 40 125 PHN Healthy Japanese volunteers
Sumiyama et al.45 70 220 (total from 2
cohorts)
PHN Healthy Japanese volunteers with no
history of herpes zoster (n5 140), herpes
zoster patients without PHN (n 5 80)
Tegeder et al.46 168 0 PPSP after lumbar discectomy (the study was
replicated in healthy controls with
experimentally induced heat, ischaemic and
mechanical pain, n 5 547)
No controls reported (authors separately
modelled the relationship between
genotype and pain intensity within the
lumbar pain cohort and the experimental
pain cohort)
Wadley et al.49 144 15 HIV-SN Nonpainful HIV-SN
Authors also modelled the relationship
between genotype and pain intensity
within the 144 with pain
* Data from a sixth cohort describing the pain sensitivity of healthy volunteers was excluded.
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3.1.4. Grading framework: “possible,” “probable,” or
“definite” neuropathic pain
Only 1 of the 20 studies cited the NeuPSIG neuropathic pain
grading system, and that single study indicated that cases satisfied
the criteria for “definite” neuropathic pain.40 Table 4 summarises
the grading criteria met by each study based on the description
of the phenotyping methodology in the article text. Only 1 study did
not describe assessing a history.6 Although only 1 study reported
using a body chart of perceived pain16 to assess whether pain
occurred in a plausible anatomical distribution, the assessment of
pain distribution could be inferred from the phenotyping descrip-
tions provided in 13 studies, even if the method of assessment was
not explicitly described.8,11,12,15,20–23,27,34,35,49 Fourteen studies
described assessing clinical signs,6,8,12,15,16,20–23,27,35,40,49 and 8
studies described the use of methods that could identify a nerve
lesion (either radiological imaging and/or QST).4,6,12,20,22,23,27,35 In
summary, 4 studies included patients identified as “possible”
neuropathic pain cases,11,34,45,46 5 included patients identified
as “probable” neuropathic pain cases,8,15,16,21,49 and only 7
included patients identified as “definite” neuropathic pain
cases.12,20,22,23,27,35,40 Six studies could not be graded
according to the criteria proposed by Treede and et al.,47 and
were classified as “undefined.”
3.2. Delphi survey
3.2.1. Participation
Twenty experts, of the 28 approached to take part in the
survey, completed round 1 (responder rate: 20/28, 71%), and
Table 2
Systematic review: summary of genetic associations
identified with neuropathic pain conditions.
Gene investigated Loci with at
least 1
significant
association
Cause of neuropathic pain
(Reference)
Multiple concordant studies
reporting associations at
specific loci
HLA-A *33 PHN36,42,45,*
HLA-B *44 PHN36,42,45,*
IL6 GGGA haplotype rs1800796 Discogenic sciatic pain27,35,†
rs1800795
rs13306435
rs1800797
Multiple discordant studies
for specific loci
COMT rs4680 Significantly associated with:
Multiple sclerosis16,‡
Not associated significantly with:
Multiple aetiologies2
PPSP (lumbar discectomy)20
Discogenic sciatic pain23
GCH1 rs3783641 Significantly associated with:
rs10483639 PPSP (lumbar discectomy)46
rs8007267 Not associated significantly with:
PPSP (lumbar discectomy)20
HIV-SN21,49,§‖
KCNS1 rs734784 Significantly associated with:
Multiple aetiologies11,‖
Not associated significantly with:
HIV-SN21,‖
HLA-DQB1 *03:02 Significantly associated with:
PPSP (inguinal hernia)15
PPSP (discogenic sciatic pain)15
Not associated significantly with:
PHN36
HLA-DRB1 *04 Significantly associated with:
PPSP (inguinal hernia)15
Not associated significantly with:
PHN36,42,45,*
HLA-DRB1 *13 Significantly associated with:
PHN42,45
Not associated significantly with:
PHN36
PPSP (inguinal hernia)15
HLA-A-B-DRB1 haplotype *33-*44-
*1302
Significantly associated with:
PHN36
Not associated significantly with:
PHN42
OPRM1 rs1799971 Significantly associated with:
DPN8
Not associated significantly with:
PPSP (lumbar discectomy)20
Solitary studies reporting
associations at novel loci
CACNG2 rs4820242 PPSP (mastectomy/lumpectomy)34
rs2284015
rs2284017
rs2284018
rs1883988
HLA-A-B *33-*44 PHN36
HLA-DQB1-DRB1
haplotype
*03:02-*04 PPSP (inguinal hernia)15
HLA-C w3 PHN36
HTR2C rs6318 Polyneuropathy6
Table 2 (continued)
Gene investigated Loci with at
least 1
significant
association
Cause of neuropathic pain
(Reference)
IL6‡ rs1800796 Discogenic sciatic pain35
rs1800795
rs13306435
KCNS1 haplotype rs4499491 HIV-SN21
rs6017486
rs6073643
MMP1 rs1799750 Discogenic sciatic pain22
TRPV1 rs920829 Multiple aetiologies4
rs8065080
rs222747
Solitary studies reporting no
associations across multiple
loci{
ABCB1 Polyneuropathy6
CYP2C19 Polyneuropathy6
CYP2D6RS PPSP (lumbar discectomy)20
HTR2A Polyneuropathy6
IL1A Discogenic sciatic pain35
IL1B Discogenic sciatic pain35
SLC6A4 Polyneuropathy6
TNFA Discogenic sciatic pain35
TNFA PHN42
Data from studies describing a single patient12 or hereditary neuropathic pain conditions40 have not been
included in the table.
* Participants in the studies by Sumiyana et al.,45 and Ozawa et al.,36 were recruited from the same study site.
† Participants in the studies by Karppinen et al.,27 and Noponen-Hietala et al.,35 were from the same cohort.
‡ Treatment response to escitalopram.
§ Participants in Wadley et al.,49 and Hendry et al.,21 were from the same cohort.
‖ Association with pain intensity, not risk of neuropathic pain.
{ Loci not listed for clarity.
DPN, diabetic polyneuropathy; HIV-SN, HIV-associated sensory neuropathy; PHN, postherpetic neuralgia;
PPSP, persistent postsurgical pain.
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17/20 (85%) indicated that they were willing to participate
in subsequent survey rounds. Round 2 invitations were sent
to 17 experts, 16 of whom completed the questionnaire
(responder rate: 16/17, 94%). Invitations to round 3 of
the survey were sent to the same round 2 17 experts, 15
of whom completed the questionnaire (responder rate:
15/17, 88%).
3.2.2. Validity and feasibility of assessing symptoms, signs,
and completing additional investigations
Figure 2 shows the level of agreement of respondents after 2
survey rounds with regards to whether symptoms, clinical
signs, and additional investigations are sensitive and specific
assessments of neuropathic pain, and whether they are
feasible for nonexperts and study participants to complete
Table 3
Systematic review: phenotyping methods reported in the article text.
Phenotyping method used Number of studies References Total summed cases/controls*
Clinical examination†
Total 15
Brief 6 6,11,15,16,39,45,‡§ Brief: 1742/862
Detailed 9 8,15,20–23,27,34,47,§ Detailed: 1346/1649
Pain rating scale 13 8,11,15,16,20–23,27,34,41,45,47,‡§ 2786/1932
History†
Total 13
Brief 9 2,11,15,16,33,36,41,45,46,‡§ Brief: 2226/1387
Detailed 4 8,12,21,47 Detailed: 326/15
Radiological imaging (MRI) 9 11,12,15,16,20,22,23,27,34,‡§ 2270/1742
Neuropathic pain identification questionnaire 2 21,47 302/15
Quantitative sensory testing (QST) 5 4,6,12,20,39 417/358
Not reported 4 1,5,19,23,‡ 175/301
Nerve conduction studies (NCS) 2 12,39 15/50
Intraepidermal nerve fibre density (IENFD) 2 12,39 15/50
Inflammatory markers 2 12,20 29/53
Body chart of perceived pain 1 16 58/108
Psychological measures (HADS) 1 20 20/53
* Cases/controls were not summed across studies if they were taken from the same existing cohort.
† “Brief” and “detiled” describe the level of detail provided in the text, not necessarily that the assessment was “brief” or “detailed.”
‡ Costigan et al.11: 6 independent cohorts each with different phenotyping methods.
§ Dominguez et al.15: 2 independent cohorts each with different phenotyping methods.
MRI, magnetic resonance imaging; HADS, Hospital Anxiety and Depression scale.
Table 4
Systematic review: neuropathic pain grading criteria achieved.
Study Criterion 1 Criterion 2 Criterion 3 Criterion 4 Grading
Plausible neuroanatomical
distribution
Appropriate
history
Altered sensory signs Evidence of lesion or disease
Armero et al.2 d Undefined*
Binder et al.4 d d Undefined*
Brasch-Andersen et al.6 d d Undefined*
Cheng et al.8 d d d Probable
Costigan et al.11,† d d Possible
Dabby et al.12 d d d d Definite
Dominguez et al.15,‡ d d d Probable
Ferna´ndez de-las-Pen˜as et al.16 d d d Probable
Hegarty and Shorten20 d d d d Definite
Hendry et al.21 d d d Probable
Jacobsen et al.23 d d d d Definite
Jacobsen et al.22 d d d d Definite
Karppinen et al.27 d d d d Definite
Nissenbaum et al.34 d d Possible
Noponen-Hietala et al.35 d d d d Definite
Ozawa et al.36 d Undefined*
Ramirez et al.40 d d d d Definite
Sato et al.42 d Undefined*
Sumiyama et al.45 d Undefined*
Tegeder et al.46 d d Possible
Wadley et al.49 d d d Probable
* Grading is undefined in terms of the criteria proposed by Treede et al.47: criteria 1 and 2 must be met to allow a working hypothesis of “possible” neuropathic pain. Additionally, criterion 3 or criterion 4 must also be met to
reach the grade of “probable” neuropathic pain. If all 4 criteria are satisfied, the grade of “definite” neuropathic pain is achieved.
† Costigan et al.11: 6 independent cohorts each containing different information about the phenotyping method and number of cases. The cohort with the lesser probability of neuropathic pain is reflected in Table 4.
‡ Dominguez et al.15: 2 independent cohorts each with different phenotyping method and cases. The cohort with the lesser probability of neuropathic pain is reflected in Table 4.
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by themselves. There was good consensus that testing clinical
signs was a sensitive method of detecting neuropathic pain as
means of identifying true “cases,” but poor consensus was
achieved for either symptoms or additional investigations
alone. There was good consensus that clinical signs and
additional investigations (but not symptoms) were specific
methods to enable the identification of true “controls.” There
was good consensus that symptoms could be reliably
assessed by nonexperts and by study participants, but that
additional investigations were not feasible for nonexperts or
study participants to assess, and that study participants could
not reliably self-assess clinical signs. The levels of agreement
across each round of the survey are shown in Supplementary
Digital Content 3 (available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A149).
3.2.3. Informative symptoms, signs, and additional
investigations
Table 5 shows the final consensus on respondents’ choices and
rankings of symptoms used in the diagnosis of neuropathic pain
for a genetic study. Strong or good consensus was achieved for
Figure 2. Delphi survey: level of agreement (5-point Likert scale, anchored at 15 strongly disagree and 55 strongly agree), and whether consensus was achieved (when
$70% of respondents disagreed/strongly disagreed, or vice versa, agreed/strongly agreed with a statement) after 2 rounds of the survey (n5 16 in the second round). (A)
Agreement on whether symptoms, clinical signs, and additional investigations are sensitive methods of detecting neuropathic pain. (B) Agreement on whether the 3
measurement domains are specificmethods for detecting neuropathic pain. (C) Agreement onwhether it is feasible for a nonspecialist to assess each of the 3measurement
domains in a research setting. (D) Agreement on whether it is feasible for study participants to self-assess symptoms and clinical signs.
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only 2 symptoms: “hot/burning” and “pain evoked by light touch.”
Fewer than one-third of respondents included “spontaneous
pain,” “paroxysmal pain,” “evoked pain,” “painful cold,” “itching,”
or “stabbing pain” in their top 5 symptoms for diagnosing
neuropathic pain.
Respondents’ choices and rankings of clinical signs used in the
diagnosis of neuropathic pain are shown in Table 6. Strong or
good consensus was achieved for only 2 signs: “dynamic
mechanical allodynia” and “altered sensation to punctate me-
chanical stimuli.” Fewer than one-third of respondents included
“temporal summation,” “altered vibration sense,” “thermal hyper-
algesia,” “altered reflexes,” “static mechanical hyperalgesia,” or
“deep mechanical hyperalgesia” in their top 5 signs to assess.
Table 7 shows the final consensus of respondents’ choices
and rankings of their top 5 additional investigations for
diagnosing neuropathic pain. The 2 top-ranked investigations
were, “QST” and “intraepidermal nerve fibre density.” In round
3, when the feasibility of nonspecialists making accurate
measurements was assessed for each of the 5 additional
investigations, only QST was rated as being feasible by 11/14
(79%) of respondents. More than 70% of respondents agreed
that all other methods of assessment were not feasible for
nonspecialists to assess neuropathic pain.
3.2.4. Perceived diagnostic certainty
Figure 3 shows the level of perceived diagnostic certainty,
according to the neuropathic pain grading system,47 in-
dicated by respondents for various assessment modalities
used alone or in combination with each other.2 There was
Table 5
Delphi survey: the number of participants who ranked symptoms in their top 5 symptoms for diagnosing neuropathic pain based
on the balance between validity and feasibility of measurement.
Symptoms*† Number of times a symptom was
listed in the top 5,
N (% participants)
Median rank (interquartile range, IQR) in
round 3
Good consensus on symptom inclusion in
the top 5 (yes: ‡70%)
Round 2:
(n 5 16)
Round 3:
(n 5 15)
Hot/burning 11 (69) 14 (93) 2 (1.25-4.5) Yes
Pain evoked by light touch 10 (62) 12 (80) 3 (2-4) Yes
Pain in a plausible anatomical
distribution
7 (44) 10 (67) 2 (1.25-3.75) —
Pain in an area of numbness 6 (38) 8 (53) 2 (2-3.25) —
Pricking/tingling/pins and needles 11 (69) 8 (53) 3 (2.5-3.25) —
Electric shocks/shooting 9 (56) 8 (53) 4 (3-4.25) —
Pain in an area of altered sensation 5 (31) 7 (47) 2 (1.5-3) —
Numbness 6 (38) 5 (33) 4 (4-5) —
Spontaneous pain 0 (0) 2 (13) 1 (1-1) —
Paroxysmal pain 3 (19) 2 (13) 4.5 (4.25-4.25) —
Evoked pain 1 (6) 1 (7) 3 (3-3) —
Painful cold 2 (12) 1 (7) 3 (3-3) —
Itching 4 (25) 1 (7) 4 (4-4) —
Stabbing pain 3 (19) 1 (7) 4 (4-4) —
* Symptoms or symptom groups identified by 20 participants in round 1 in an open question to list 4 symptoms that provide the best balance between validity and feasibility when diagnosing neuropathic pain.
† Symptoms are listed according to number of times they were listed in participants’ top 5 in round 3, and then by the median rank received by listed symptoms in round 3 (1 highest ranked, 5 lowest rank).
— indicates that no consensus reached at the $70% threshold level after 2 rounds.
Table 6
Delphi survey: the number of participantswho ranked a clinical sign in their top 5 signs for diagnosing neuropathic pain based on
the balance between validity and feasibility of measurement.
Clinical sign*† Number of times a clinical sign was
listed in the top 5 (% participants)
Median rank (IQR) in round 3 Good consensus on clinical sign inclusion in
the top 5 (yes: ‡70%)
Round 2: (n5 16) Round 3: (n5 15)
Dynamic mechanical allodynia 13 (81) 14 (93) 1 (1-2) Yes
Altered sensation to punctate mechanical
stimuli
6 (38) 12 (80) 2 (1-4.25) Yes
Hypoaesthesia to punctate mechanical stimuli 8 (50) 10 (67) 3 (2-4) —
Punctate mechanical hyperalgesia 7 (44) 9 (60) 2 (2-4) —
Cold allodynia 7 (44) 9 (60) 3 (2-4) —
Thermal hypoaesthesia 5 (31) 6 (40) 2.5 (2-4.5) —
Temporal summation 6 (38) 4 (27) 2 (1-3.25) —
Altered vibration sense 5 (31) 4 (27) 3 (2-4.25) —
Thermal hyperalgesia 2 (12) 3 (20) 3 (2.5-3.5) —
Altered reflexes 2 (12) 3 (20) 3 (2.5-4) —
Static mechanical hyperalgesia 5 (31) 1 (7) 3 (3-3) —
Deep mechanical hyperalgesia 1 (6) 1 (7) 4 (4-4) —
* Clinical signs identified by 20 participants in round 1 in an open question to list 4 clinical signs that provide the best balance between validity and feasibility when diagnosing neuropathic pain.
† Signs are listed according to number of times they were listed in participants’ top 5 in round 3, and then by the median rank received by listed signs in round 3 (1 highest ranked, 5 lowest rank).
— indicates that no consensus reached at the $70% threshold level after 2 rounds.
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unanimous consensus that a combination of “additional
investigations, clinical signs, symptoms, body chart, and
patient history” provided a diagnosis of “definite” neuropathic
pain. All respondents also indicated that combinations of:
“additional investigations, clinical signs and symptoms,” and
“clinical signs, symptoms, body chart, and patient history”
provided a diagnosis of at least “probable” neuropathic
pain. The poorest perceived diagnostic certainty was asso-
ciated with assessments that only included “additional
investigations.” The levels of agreement across each round
of the survey are shown in Supplementary Digital Content 4
(available online as Supplemental Digital Content at http://
links.lww.com/PAIN/A150).
3.2.5. Additional phenotyping measures
The level of agreement on which measurements should be
included in an assessment of neuropathic pain (in addition to
Table 7
Delphi survey: the number of participants who ranked an additional investigation in their top 5 symptoms for diagnosing
neuropathic pain based on the balance between validity and feasibility of measurement.
Additional investigations*† Number of times an investigation was listed
(% participants)
Median rank (IQR) in round 3
Round 2: (n 5 16) Round 3: (n 5 15)
Quantitative sensory testing 12 (75) 14 (93) 1 (1-1.75)
Intraepidermal nerve fibre density 12 (75) 13 (87) 2 (2-3)
Nerve conduction studies 8 (50) 13 (87) 3 (2-3)
Magnetic resonance imaging 6 (38) 12 (80) 5 (4-5)
Evoked potentials 7 (44) 11 (73) 4 (3.5-4)
* Additional investigations identified by 20 participants in round 1 in an open question to list 4 additional investigations that provide the best balance between validity and feasibility when diagnosing neuropathic pain. Note: only
5 additional investigations were provided for participants to rank in round 2 and 3, so the number of times an investigation was listed was not used to assess consensus.
† Additional investigations are listed according to the number of times they were listed in participants’ top 5 in round 3, and then by the median rank received by listed items in round 3 (1 highest ranked, 5 lowest rank).
Figure 3. Delphi survey: level of diagnostic certainty achieved by individual assessment types and combinations of these assessments when assessing
whether a pain is “definite,” “probable,” or “possible” neuropathic pain.2 Results shown are after 2 rounds of the Delphi survey (n 5 16 in the second
round).
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symptoms, signs, and additional investigations) is shown in
Table 5 (and Supplementary Digital Content 5, available
online as Supplemental Digital Content at http://links.lww.
com/PAIN/A151). After 2 rounds of the survey, there was
strong consensus that assessment should include a history
and a body chart to indicate pain distribution. Prompted by
discussions at the consensus meeting (see below), in round 3
of the survey, we probed what the body chart and history
should include. Having $70% of respondents in agreed or
strong agreement, the strongest consensus was for the
following items assessing patient history: “a previous di-
agnosis of neuropathic pain by another clinician” and “risk
factors for having neuropathic pain” (see Supplementary
Digital Content 6, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A152). On the body
chart of perceived pain, 75% (12/16) of respondents indicated
that, in the event of more than 1 pain site, the “main pain and
any other pains” should be identified. Almost two-thirds (64%,
9/14) believed that a checklist of body regions was a suitable
substitute for a body chart cartoon.
3.3. Consensus meeting
The primary goal of the meeting was the development
of a consensus statement on “entry level” phenotyping
requirements for genetic studies of neuropathic pain in human
adults.
3.3.1. Consensus statement development
Participants agreed that there is an inverse relationship
between accurate case ascertainment of neuropathic pain
and large-scale implementation thereof in population-based
studies. We agreed that the entry-level phenotyping require-
ments included in the statement should form the basis of
establishing neuropathic pain “caseness” for genetic studies.
This basic phenotyping must allow the addition of more in-
depth measures for higher level phenotyping to allow the
identification of genetic loci for specific aspects of neuro-
pathic pain other than just presence or absence of neuro-
pathic pain. The entry-level requirements should provide
a framework to guide researchers on study design and
provide a platform to appraise their findings to allow feasible
and valid assessment for the presence or absence of
neuropathic pain in large population-based genetic studies.
3.3.2. “Entry level” phenotyping for genetic studies,
a consensus
Box 1 shows the agreedNeuroPPIC entry-level requirements that
would allow the classification of participants as having “possible”
neuropathic pain. Consistent with the findings of the Delphi
survey, a neuropathic pain “case” must have:
(1) painwith neuropathic characteristics (ie, positive on a validated
screening questionnaire; or pain, ie, “hot/burning” and/or “pain
evoked by light touch”);
(2) a distribution or location of this pain that is anatomically
consistent with an underlying somatosensory lesion or disease
(as indicated by a body chart or body parts checklist); and
(3) further characterisation in the form of a clinical history
(duration and intensity of pain and presence of other pains)
and demographic information relevant to the population/
disease being studied.
Box 1
NeuroPPIC consensus statement on entry-level phenotyping
for genetic studies of neuropathic pain in humans.
A neuropathic pain “control” would be negative for (1) and (2),
but will be characterised as (3) as clinically relevant.
The panel agreed that if there are discrepancies between
the findings from the screening tool, anatomical distribution,
and patient history, then the participant should be excluded
from the study. Overall, these 3 components only satisfy
criteria 1 and 2 of the NeuPSIG grading system, and thus the
level of diagnostic certainty achieved is “possible” neuro-
pathic pain.47
While acknowledging the lack of a “gold standard,” we
agreed that achieving greater diagnostic certainty (ie, “proba-
ble” or “definite” neuropathic pain) is desirable. Such greater
diagnostic certainty requires additional assessments that
confirm the presence of positive and/or negative sensory signs
(for “probable” neuropathic pain) or provide direct evidence of
a lesion to the somatosensory nervous system (for “definite”
neuropathic pain) in the affected area. More extensive pheno-
typing could allow case stratification into additional pain
phenotypes based on sensory and psychological parameters
(eg, pain catastrophizers vs noncatastrophizers; pinprick
hypoaesthesia vs pinprick hyperaesthesia).
The panel additionally agreed that it could not currently be
prescriptive in the selection of additional phenotyping measures
Entry-level phenotyping
Establishes the presence of “possible” neuropathic pain
The results of the screening tool should be weighted highest, and then the body
map or checklist and pain history equally below*
1. Symptom assessment using
neuropathic pain screening tools
The symptom component of at least 1
validated neuropathic pain screening tool
(eg, DN4-interview, painDETECT, S-
LANSS, or other)†
Screening tools should have been
validated in:
The language and culture of the
target population(s)
The condition(s) under investigation
2. Anatomical distribution of pain A body chart or checklist for specifying the
anatomical region affected by the pain‡
3. History§ Pain duration (eg, date of onset, age at
onset, or duration of symptoms)
Pain intensity over the last 24 h (eg, 0-10
numerical pain rating scale or 100-mm
visual analogue scale)‖
The presence of any diagnosed chronic
pain syndromes (eg, a checklist of
common pain pathologies)
Demographic information (including, but
not limited to: age, sex, ethnicity, and
relevant comorbid medical conditions)
* If there is a discrepancy between the outcome of the screening tool, pain history, and body chart, it might be
appropriate to exclude the participant from both case and control groups or to stratify the genetic analysis
with a weighted importance on each of the entry level criteria.
† Participants in the meeting were most familiar with the DN4-interview: Douleur Neuropathique en 4
questions-interview,5 S-LANSS: Self-report Leeds assessment of neuropathic symptoms and signs,3 and
painDETECT.18
‡ Round 3 of the Delphi survey identified ($70% of respondents) that “main pain and any other pains” should
be recorded, with the site of the main pain being noted (64% of respondents agreed that a checklist of body
parts could be used instead of an body chart cartoon).
§ Round 3 of the Delphi survey identified ($70% of respondents) that “a previous diagnosis of neuropathic
pain by another clinician” and “risk factors for having neuropathic pain” should be included in the history.
‖ Pain intensity should not be used as a predetermined cutoff value for case ascertainment.
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to use beyond determination of “caseness,” as the choice was
dependent on factors such as the feasibility of making measure-
ments based on cost and practicality, the population and disease
being studied (eg, central vs peripheral neuropathic pain), and the
research question being addressed. However, choice of additional
measures to use when assessing “caseness” should be consistent
with the NeuPSIG grading system for neuropathic pain. See
Supplementary Digital Content 7 for examples of additional
phenotypes voiced at the meeting (available online as Supple-
mental Digital Content at http://links.lww.com/PAIN/A153).
3.3.3. Misclassification
We agreed that misclassification of cases and controls signifi-
cantly affects the power of studies to detect true genetic
associations and the reproducibility of findings. We identified
several key factors that may contribute to misclassification of
cases and controls (Box 2). These factors can be divided into 2
broad categories: (1) misclassification due to on incomplete pain
history; and (2) misclassification due to an imperfect sensitivity
and specificity of available assessments for neuropathic pain.
Ideally, where reasonable doubt arises after applying the
phenotyping criteria proposed here, an individual should be
considered as neither a case nor a control, and removed from
analysis.
Box 2
Possible factors thatmay contribute tomisclassification of
neuropathic pain.
4. Discussion
The unequivocal identification of genetic sequence variants
correlating with complex diseases requires sample sizes ranging
from large cohorts (including hundreds to thousands of partic-
ipants) when interrogating a few candidate genes, to much larger
sample sizes that include tens of thousands of participants when
studying the whole genome31,51 and extensive phenotyping.50
Unlike Mendelian disorders, the genetic contribution to complex
diseases such as chronic pain is generally attributed to
contributions of a high number of risk variants, including single-
nucleotide polymorphisms, most with a small effect. In neuro-
pathic pain, a number of relevant candidate genes have been
identified in animal studies, and an even smaller number show
some association in humans, as shown above. However, none of
these single-nucleotide polymorphisms has been consistently
replicated in large human cohorts.32 This is an essential step in
confirming the validity of these genetic findings.7 Failure to
replicate, in humans, a finding originally made in humans may be
because the original finding was spurious, study cohorts were
underpowered, there was heterogeneity in the studied pain
condition or study populations, or there were differences in the
phenotyping of cases and/or controls. The ideal control in
a genetic study would be an age- and sex-matched individual
who was exposed to the same lesion or disease of the
somatosensory system as the case, but who did not develop
neuropathic pain.30 Rigorous, standardised phenotyping is
therefore crucial. Failure to translate a finding from rodent models
to humans may likewise be because the original finding was
spurious, the human cohort was underpowered, the phenotypes
were different, or the gene under study does not play a role in the
tested human condition. Pain geneticists who seek candidate
neuropathic pain genes in animal models should try to
approximate their phenotypes to those used by human pain
geneticists, although animal phenotypes also require consider-
able further refinement in terms of both internal and external
validity.37
The need for a consensus-based, rather than purely evidence-
based approach to phenotyping neuropathic pain for genetic
studies reflects the absence of “gold standards” for both case
definition (what is neuropathic pain?) and case attribution (how do
we know who has neuropathic pain?). Through a process of
systematic literature review, Delphi survey, and expert consensus
meeting, we have identified an agreed “entry level” approach to
phenotyping cases and controls for studies of genetic associa-
tions with neuropathic pain in adults. This phenotype is based on
establishing the presence or absence of “possible” neuropathic
pain, according to the most internationally agreed system for
classifying neuropathic pain clinically.47 This uses validated
symptom-based screening tools and a body chart or checklist
to determine neuroanatomical relevance. Further details, also
collected by questionnaire, include pain history (duration, in-
tensity, and formal diagnoses) and demographic information (Box
1). We present this “entry level” approach as the minimum
phenotyping standard for genetic association studies on neuro-
pathic pain in adults, with the expectation that more extensive
phenotyping should build on this “entry level” approach, as
required and as resources allow. Adoption of these NeuroPPIC
phenotyping guidelines will facilitate comparison and collabora-
tion between researchers, including replication studies andmeta-
analyses. The guidelines are applicable to different types of
genetic studies of neuropathic pain, from targeted studies
interrogating a few genetic loci that use specific neuropathic pain
traits to hypothesis-free genome-wide studies with large sample
sizes. They will also apply to studies with a larger array of
phenotypes, including more detailed pain traits, psychosocial
traits, and pharmacological screens. Our systematic review
identified the lack of a consistent approach to phenotyping
neuropathic pain, poor reporting of phenotyping methodologies,
and failure to adequately describe control groups (especially
when “healthy controls” were used). These limitations are likely to
have contributed to inconsistent and nonreplicated findings, and
highlight the need for the NeuroPPIC process we have
completed.
Although we have recommended the use of validated
assessment instruments where possible, our guidelines are not
intended to guide case definition, attribution, or classification for
History
Past episodes of neuropathic pain, but neuropathic pain not currently active
Changing neuropathic pain phenotype over time
Multiple chronic pain conditions
Measurement
The specificity of questionnaires (ie, ability to correctly identify controls)
Heterogeneity of endophenotypes* within neuropathic pain syndromes
Similarities in endophenotypes* across neuropathic pain syndromes
Inconsistent mode of measurement (eg, face-to-face, postal, Web-based)
Cross-cultural and language validity of screening tools and questionnaires
Assessment of the “main pain” when there are multiple pain diagnoses or sites†
* Subphenotypes within the broader classification of having neuropathic pain (eg, neuropathic pain
associated with hypoaesthesia to pinprick vs neuropathic pain associated with hyperaesthesia to pinprick).
† Study participants with multiple pain sites of mixed origin (neuropathic and nonneuropathic) may be
misclassified as controls if only their “main pain” is characterised and that pain is nonneuropathic in origin.
Nevertheless, the panel agreed that asking participants to characterise their “main pain” was the most
practical approach to assessing patients with multiple pain sites (especially if using a self-assessment
approach), but were possible, a more complete assessment of such participants should be made. The issue is
less of problem when investigating pain of known aetiology (eg, postherpetic neuralgia, postamputation pain),
and patients can be directed to focus on the pain produced (or not) by this aetiology.
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clinical research or neurological practice, where more individuals
certainty may be required, based on empirical evidence of the
presence or absence of neuropathic pain and the known
likelihood of identifying this through any assessment. This will
require separate work, and is the subject of an ongoing NeuPSIG
project. Instead, our consensus-based development provides
a standardised approach for use by researchers in different
settings internationally, in the expectation that it will allow
a common approach to identifying the presence or absence of
“possible” neuropathic pain for genetic research. However, future
research should validate the “entry level” phenotype against best
available clinical assessments, with a view to calculating
sensitivity, specificity, and positive and negative predictive values.
Delphi surveys are an accepted method of achieving consen-
sus on complex issues in science and medicine,13,39 including
pain medicine, in which a “gold standard” does not exist (as in
neuropathic pain26). For example, previous studies have used
Delphi methods to develop a standard definition for back pain14
and neuropathic pain44 for use in prevalence studies, and to
develop guidelines for the management of hip and knee
osteoarthritis.52 Identified limitations of the method include its
basis in the opinions of a selected group of survey participants,
and the potential for the outcome to be a diluted version of “best
opinion,”39 criticisms that could also be levelled at consensus
meetings. There is no agreed optimum number or composition of
panellists or rounds for Delphi surveys or consensus meetings.
Our intention was to include a range of disciplines rather than to
be comprehensive in our inclusion, and to include a similar
number of participants and rounds as in previous successful
studies.32,44,52 This would allow the processes to remain
manageable, while ensuring a contribution of expertise from
each relevant discipline and consistency with existing research.
Contributors were identified on the basis of their published track
record in neuropathic pain phenotyping and/or genetics. It is
possible that a different group of contributors would have
produced different outcomes, and unanimity was not obtained
for any item in the survey. It is, though, notable that good or very
good consensus was achieved in many useful aspects of this
Delphi survey, and agreement on the NeuroPPIC “entry level”
phenotyping approach was achieved after intense deliberations.
We are, therefore, confident that our findings reflect the views of
the relevant research community, resulting in adoption of
NeuroPPIC’s approach in future genetic studies.
NeuroPPIC has only provided a consensual statement on the
nature of “entry level” phenotyping and instruments that can be
used to accomplish successful classification of participants as
having vs not having neuropathic pain. These NeuroPPIC
guidelines are for the basic phenotyping requirements for any
genetic study of neuropathic pain in adults. It is notable that this
“entry level” phenotyping is based only on study participants’
responses to questions and does not include clinical examination
or further investigations. This “entry level” phenotyping approach
will allow inclusion in large-scale questionnaire-based surveys.
Our Delphi survey confirms that augmenting a simple symptom
checklist by questions on pain bodily distribution and history will
allow the identification of “possible” neuropathic pain. Although
symptoms could be confined to a smaller list of verbal descriptors
(eg, “hot/burning pain” and “pain evoked by light touch”), the use
of a slightly longer but well-validated screening instrument will
prevent the need for validation of a new questionnaire instrument.
Available screening instruments include DN4, S-LANSS, and
PainDETECT, but we aremaking no statement on which of these,
if any, is to be preferred. This approach conforms to the “very
general” approach outlined in the introduction and will be suitable
for large-scale population-based studies, including those in
which neuropathic pain is just one of a number of conditions to
be phenotyped. More extensive phenotyping of additional
aspects of neuropathic pain will require a more detailed set of
assessments, to allow for inclusion of “very specific” phenotypes.
Although NeuroPPIC was able to provide some pointers towards
these levels, we have not yet furnished agreed guidelines on the
nature of these phenotypes and the instruments to collect them,
and this will require further work, building on the “entry level”
approach. Any additional, more extensive phenotyping should,
however, be consistent with the “entry level” approach, to allow
specificity to be built in to the basic model. This will allow
incremental approaches to phenotyping within a large cohort,
and the testing for replication of associations identified in
extensively phenotyped cohorts.
4.1. Reporting recommendations
The STREGA29 and GRIPS24,25 guidelines provide a framework
for reporting genetic epidemiology studies and indicate that
participant eligibility criteria and methods of participant selection
and screening, including subsets of participants, should be
reported. Moreover, in case–control studies, this information
should be reported for both cases and controls. To facilitate clear
and open reporting of phenotyping in genetic studies of
neuropathic pain, we propose the following NeuroPPIC guide-
lines for describing study participants: (1) a description of
sampling methodology and participant eligibility criteria; (2) an
unambiguous description of the case definition used to define the
presence or absence of neuropathic pain in cases and controls;
(3) a description of the methods used to assess each component
of the case definition and the criteria used to define abnormal
function for each method used; and (4) a summative statement of
whether the case definition satisfies the criteria for “possible,”
“probable,” or “definite” neuropathic pain based on the latest
grading guidelines (currently Treede et al.47). These recommen-
dations are consistent with the recommendations made by
STREGA and GRIPS and should be used in addition to those 2
guidelines.
By providing an “entry level” phenotype and making
recommendations on the reporting of the criteria andmethods
used for caseness and its ascertainment, we believe that
greater consistency and transparency can be achieved in
studies on the genetics of neuropathic pain in adult humans.
These improvements will facilitate advancements in the field
by enabling collaboration between research groups, replica-
tion of discoveries of contributing genetic variants, meta-
analyses, and translation from the laboratory to the general
population, and back again.
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